Targeted Innovation in Biliary Tract Cancer: The COMPANION-002 Trial Results on October 24, 2026 Posted by
The Recovery Paradox: Why Your Post-Workout Routine Might Be Holding You Back on October 24, 2026 Posted by
Unmasking the Invisible: New Immune Cell Discovery Offers Hope Against Aggressive Lung Cancer on October 24, 2026 Posted by
Unveiling a New Horizon in Mobility: UPnRIDE and Kessler Foundation Forge Groundbreaking Research Partnership on October 24, 2026 Posted by
Empowering the Next Generation: Active Minds Unveils the 2026-2027 Student Advisory Committee Cohort on October 24, 2026 Posted by
The New Era of Bipolar Care: How Recent Breakthroughs in Science are Redefining "Living Well" on October 24, 2026 Posted by
The Hidden Calorie Spike: Why Your Morning Coffee is Becoming Less "Black" on October 24, 2026 Posted by
Targeted Innovation in Biliary Tract Cancer: The COMPANION-002 Trial Results on October 24, 2026 Posted by
The Recovery Paradox: Why Your Post-Workout Routine Might Be Holding You Back on October 24, 2026 Posted by
Unmasking the Invisible: New Immune Cell Discovery Offers Hope Against Aggressive Lung Cancer on October 24, 2026 Posted by
Unveiling a New Horizon in Mobility: UPnRIDE and Kessler Foundation Forge Groundbreaking Research Partnership on October 24, 2026 Posted by
Posted in Sleep Health A Paradigm Shift in Sleep Medicine: FDA Approves Orzeyful (oveporexton) for Narcolepsy Type 1 on August 31, 2026
Posted in Sleep Health A New Era in Sleep Medicine: FDA Approves Orzeyful to Address the Root Cause of Narcolepsy Type 1 on August 24, 2026
Posted in Sleep Health A Paradigm Shift in Sleep Medicine: FDA Approves Orzeyful to Address the Root Cause of Narcolepsy Type 1 on August 17, 2026
Posted in Sleep Health A Paradigm Shift in Sleep Medicine: FDA Approves Orzeyful to Target the Root Cause of Narcolepsy Type 1 on August 7, 2026
Posted in Medical Innovations A New Dawn for Narcolepsy: Takeda’s Orzeyful Signals a Paradigm Shift in Sleep Medicine on August 6, 2026
Posted in Respiratory Health A New Dawn for Narcolepsy Type 1: FDA Approves Orzeyful, the First Orexin-Targeting Therapy on August 6, 2026
